229 related articles for article (PubMed ID: 29662195)
21. Generation of fusion proteins for selective occlusion of tumor vessels.
Kessler T; Schwöppe C; Liersch R; Schliemann C; Hintelmann H; Bieker R; Berdel WE; Mesters RM
Curr Drug Discov Technol; 2008 Mar; 5(1):1-8. PubMed ID: 18537561
[TBL] [Abstract][Full Text] [Related]
22. Combinatorial effects of doxorubicin and retargeted tissue factor by intratumoral entrapment of doxorubicin and proapoptotic increase of tumor vascular infarction.
Stucke-Ring J; Ronnacker J; Brand C; Höltke C; Schliemann C; Kessler T; Schmidt LH; Harrach S; Mantke V; Hintelmann H; Hartmann W; Wardelmann E; Lenz G; Wünsch B; Müller-Tidow C; Mesters RM; Schwöppe C; Berdel WE
Oncotarget; 2016 Dec; 7(50):82458-82472. PubMed ID: 27738341
[TBL] [Abstract][Full Text] [Related]
23. Critical role of flanking residues in NGR-to-isoDGR transition and CD13/integrin receptor switching.
Curnis F; Cattaneo A; Longhi R; Sacchi A; Gasparri AM; Pastorino F; Di Matteo P; Traversari C; Bachi A; Ponzoni M; Rizzardi GP; Corti A
J Biol Chem; 2010 Mar; 285(12):9114-23. PubMed ID: 20064928
[TBL] [Abstract][Full Text] [Related]
24. Modification of cyclic NGR tumor neovasculature-homing motif sequence to human plasminogen kringle 5 improves inhibition of tumor growth.
Jiang W; Jin G; Ma D; Wang F; Fu T; Chen X; Chen X; Jia K; Marikar FM; Hua Z
PLoS One; 2012; 7(5):e37132. PubMed ID: 22590653
[TBL] [Abstract][Full Text] [Related]
25. Systemic and tumor-targeted delivery of siRNA by cyclic NGR and isoDGR motif-containing peptides.
Huang Y; Cheng Q; Jin X; Ji JL; Guo S; Zheng S; Wang X; Cao H; Gao S; Liang XJ; Du Q; Liang Z
Biomater Sci; 2016 Mar; 4(3):494-510. PubMed ID: 26783563
[TBL] [Abstract][Full Text] [Related]
26. Inhibition of tumor growth by RGD peptide-directed delivery of truncated tissue factor to the tumor vasculature.
Kessler T; Bieker R; Padró T; Schwöppe C; Persigehl T; Bremer C; Kreuter M; Berdel WE; Mesters RM
Clin Cancer Res; 2005 Sep; 11(17):6317-24. PubMed ID: 16144936
[TBL] [Abstract][Full Text] [Related]
27. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy.
Pastorino F; Brignole C; Marimpietri D; Cilli M; Gambini C; Ribatti D; Longhi R; Allen TM; Corti A; Ponzoni M
Cancer Res; 2003 Nov; 63(21):7400-9. PubMed ID: 14612539
[TBL] [Abstract][Full Text] [Related]
28. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of (188)Re-labeled NGR-VEGI protein for radioimaging and radiotherapy in mice bearing human fibrosarcoma HT-1080 xenografts.
Ma W; Shao Y; Yang W; Li G; Zhang Y; Zhang M; Zuo C; Chen K; Wang J
Tumour Biol; 2016 Jul; 37(7):9121-9. PubMed ID: 26768609
[TBL] [Abstract][Full Text] [Related]
30. The neovasculature homing motif NGR: more than meets the eye.
Corti A; Curnis F; Arap W; Pasqualini R
Blood; 2008 Oct; 112(7):2628-35. PubMed ID: 18574027
[TBL] [Abstract][Full Text] [Related]
31. MicroPET imaging of CD13 expression using a (64)Cu-labeled dimeric NGR peptide based on sarcophagine cage.
Li G; Wang X; Zong S; Wang J; Conti PS; Chen K
Mol Pharm; 2014 Nov; 11(11):3938-46. PubMed ID: 25054774
[TBL] [Abstract][Full Text] [Related]
32. Tumor uptake of the RGD dimeric probe (99m)Tc-G3-2P4-RGD2 is correlated with integrin αvβ3 expressed on both tumor cells and neovasculature.
Liu Z; Jia B; Shi J; Jin X; Zhao H; Li F; Liu S; Wang F
Bioconjug Chem; 2010 Mar; 21(3):548-55. PubMed ID: 20184307
[TBL] [Abstract][Full Text] [Related]
33. The uptake exploration of 68Ga-labeled NGR in well-differentiated hepatocellular carcinoma xenografts: Indication for the new clinical translational of a tracer based on NGR.
Gao Y; Wang Z; Ma X; Ma W; Zhao M; Fu T; Li G; Wang S; Wang Z; Yang W; Kang F; Wang J
Oncol Rep; 2017 Nov; 38(5):2859-2866. PubMed ID: 28901442
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and evaluation of 64Cu-labeled monomeric and dimeric NGR peptides for MicroPET imaging of CD13 receptor expression.
Chen K; Ma W; Li G; Wang J; Yang W; Yap LP; Hughes LD; Park R; Conti PS
Mol Pharm; 2013 Jan; 10(1):417-27. PubMed ID: 23190134
[TBL] [Abstract][Full Text] [Related]
35. The recombinant EGFR/CD13 bi-targeted fusion protein induces apoptosis and blocks tube formation.
Sheng W; Gong J; Jiang M; Zhen Y
Oncol Rep; 2017 Dec; 38(6):3507-3514. PubMed ID: 29130101
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of
Zhao M; Yang W; Zhang M; Li G; Wang S; Wang Z; Ma X; Kang F; Wang J
Tumour Biol; 2016 Sep; 37(9):12123-12131. PubMed ID: 27220318
[TBL] [Abstract][Full Text] [Related]
37. Multi-targeting NGR-modified liposomes recognizing glioma tumor cells and vasculogenic mimicry for improving anti-glioma therapy.
Huang D; Zhang S; Zhong T; Ren W; Yao X; Guo Y; Duan XC; Yin YF; Zhang SS; Zhang X
Oncotarget; 2016 Jul; 7(28):43616-43628. PubMed ID: 27283987
[TBL] [Abstract][Full Text] [Related]
38. High-yield expression, purification and characterization of tumor-targeted IFN-alpha2a.
Meng J; Yan Z; Wu J; Li L; Xue X; Li M; Li W; Hao Q; Wan Y; Qin X; Zhang C; You Y; Han W; Zhang Y
Cytotherapy; 2007; 9(1):60-8. PubMed ID: 17354103
[TBL] [Abstract][Full Text] [Related]
39. 13F-1, a novel 5-fluorouracil prodrug containing an Asn-Gly-Arg (NO2) COOCH3 tripeptide, inhibits human colonic carcinoma growth by targeting Aminopeptidase N (APN/CD13).
Cui SX; Zhang HL; Xu WF; Qu XJ
Eur J Pharmacol; 2014 Jul; 734():50-9. PubMed ID: 24726845
[TBL] [Abstract][Full Text] [Related]
40. Targeting tumor angiogenesis: comparison of peptide and polymer-peptide conjugates.
Line BR; Mitra A; Nan A; Ghandehari H
J Nucl Med; 2005 Sep; 46(9):1552-60. PubMed ID: 16157540
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
